InvestorsHub Logo
Followers 219
Posts 247348
Boards Moderated 2
Alias Born 04/06/2006

Re: Tuff-Stuff post# 554841

Monday, 12/22/2014 6:16:11 AM

Monday, December 22, 2014 6:16:11 AM

Post# of 648882
AbbVie's new hepatitis C drug gets boost

The price war over hepatitis C drugs continues, after Express Scripts (NASDAQ:ESRX) announced that it will only cover AbbVie's (NYSE:ABBV) newly approved Viekira Pak, which received clearance from the FDA on Friday.
The move will help the drug maker take market share away from Gilead Sciences (NASDAQ:GILD) and J&J (NYSE:JNJ), which make blockbuster hep C drugs, including Sovaldi, Harvoni and Olysio.
AbbVie's Viekira Pak will have a price of $83,319, although the agreement with Express Scripts involves a significant discount to that price.

Pray for A Pain Free Day!

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.